Ask the Experts: Formulation

In this podcast, Douglas DiRuggiero, PA-C, DMSc, a Physician Assistant specializing in medical and surgical dermatology, discusses his experience using the topical medication ZORYVE^® (roflumilast), a steroid-free targeted topical for patients with inflammatory skin conditions plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Mr. DiRuggiero highlights the specific ZORYVE formulations across indications, noting their overall effectiveness and tolerability profiles.

In atopic dermatitis clinical trials, 2x as many patients achieved vIGA-AD Success at Week 4 with ZORYVE (31%, n=884) vs vehicle (14%, n=453).

In seborrheic dermatitis clinical trials, 77% of patients achieved IGA Success at Week 8 with ZORYVE (n=458) vs vehicle (53%, n=225).

In plaque psoriasis clinical trials, 6x more patients achieved IGA Success at Week 8 with ZORYVE (40%, n=576) vs vehicle (7%, n=306).

ZORYVE is safe and well tolerated across body locations—there are low rates of stinging or burning in each indication—1.6% in atopic dermatitis, 1.3% in seborrheic dermatitis, and 0.4% in plaque psoriasis. Additionally, all formulations are not associated with folliculitis, atrophy, striae, or HPA-axis suppression. There were also low rates of discontinuation due to adverse events—in atopic dermatitis, 1.6% and 1.1% with ZORYVE and vehicle, respectively; in the seborrheic dermatitis STRATUM trial, fewer than 1%; and in plaque psoriasis, 1%.

INDICATIONS

ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

For more dermatologic disorders content, visit the Disease State Hub. 

HPA=hypothalamic-pituitary-adrenal; IGA=Investigator's Global Assessment; IGA Success=Achievement of Clear (0)/Almost Clear (1) and a ≥2-grade improvement from baseline; vIGA-AD™=Validated Investigator Global Assessment-Atopic Dermatitis; vIGA-AD Success=Achievement of Clear (0)/Almost Clear (1) and a ≥2-grade improvement from baseline.

Marketed by Arcutis Biotherapeutics, Inc. and Kowa Pharmaceuticals America, Inc.

© 2025 Arcutis Biotherapeutics, Inc. All rights reserved. US-COM-PTF-00652 08/25